The Capital Partnership
The Capital Partnership is an independent asset manager established in 1998, based in London, with additional offices in Dubai. It provides a diverse range of asset management and wealth preservation services to institutional and private investors, including families and large institutions in the EMEA region. Initially created to serve the sophisticated investment needs of the founding partners' families, the firm has successfully expanded its offerings to address the asset management requirements of various clients. The Capital Partnership employs a multi-strategy approach, investing in both public and private markets. The group's ultimate holding company is incorporated in the Dubai International Financial Centre, while its UK operating subsidiary is authorized and regulated by the Financial Conduct Authority. Through its expertise, The Capital Partnership assists clients in navigating the complexities of asset growth and preservation.
28 past transactions
Supira Medical
Series E in 2025
Supira Medical develops a percutaneous ventricular assist device (pVAD) designed to provide temporary mechanical support during high-risk coronary interventions and cardiogenic shock. Its solution assists the native pumping action of the heart, enabling patients to undergo necessary procedures.
Laza Medical
Series A in 2023
Laza Medical is a startup developing an AI-powered robotic imaging system for cardiovascular interventions. Its solution aims to optimize procedural workflows and enhance imaging standards in cardiac procedures, benefiting a wide range of clinicians.
Supira Medical
Series D in 2023
Supira Medical develops a percutaneous ventricular assist device (pVAD) designed to provide temporary mechanical support during high-risk coronary interventions and cardiogenic shock. Its solution assists the native pumping action of the heart, enabling patients to undergo necessary procedures.
Akura Medical
Series B in 2023
Akura Medical develops next-generation thrombectomy devices designed to simplify clot removal with a single-pass procedure, offering an easy-to-use solution to efficiently remove blood clots. The company also provides a range of surgical, medical, dental, and veterinary instruments to support clinicians in addressing venous thromboembolism and other clot-related conditions across diverse patient populations.
Myra Vision
Series B in 2023
Myra Vision develops innovative surgical techniques aimed at enhancing glaucoma treatment. Its core technology enables significant intraocular pressure reduction while minimizing the risk of hypotony, offering physicians an improved platform for treating moderate to advanced glaucoma.
Tioga Cardiovascular
Series C in 2023
Tioga Cardiovascular is a privately held company that specializes in developing valve replacement solutions for mitral and tricuspid applications. The company focuses on creating medical equipment technology that employs a transcatheter approach, which is both procedurally simpler and less invasive than traditional methods. By prioritizing innovation in valve replacement devices, Tioga Cardiovascular aims to enhance the effectiveness and success of heart surgeries, thereby improving patient outcomes and providing elegant solutions for healthcare professionals.
Atia Vision
Series E in 2022
Atia Vision, Inc. is a medical device company based in Campbell, California, specializing in the development of innovative ophthalmic solutions. Founded in 2012, the company focuses on creating modular presbyopia-correcting intraocular lenses, which address the needs of the intraocular lens replacement market. Atia Vision's technology features an accommodating base that responds to the ciliary muscles of the eye, simulating natural accommodation and allowing for subsequent refractive corrections. This approach restores the full range of functional vision for cataract patients, effectively improving patient outcomes by eliminating the need for glasses. The company's commitment to advancing eye care is reflected in its goal to enhance the quality of life for individuals through innovative medical devices that expedite market entry while minimizing risk.
Adona Medical
Series B in 2022
Adona Medical innovates interventional approaches for managing heart failure, a progressive condition affecting millions globally. Its platform aims to improve care by enabling personalized management of cardiac patients through advanced sensor and shunt technologies.
Supira Medical
Series C in 2022
Supira Medical develops a percutaneous ventricular assist device (pVAD) designed to provide temporary mechanical support during high-risk coronary interventions and cardiogenic shock. Its solution assists the native pumping action of the heart, enabling patients to undergo necessary procedures.
Mindstep
Seed Round in 2022
Mindstep is a developer of cognitive and mental health digital therapeutics, with a mission to improve brain health and reduce the risk of dementia for one million individuals. Founded by medical professionals, the company prioritizes accessibility, empathy, and scientific rigor, reflecting core values typical of the NHS. Mindstep utilizes a platform that merges machine learning with clinical research, creating digital solutions that provide users with a personalized healthcare experience. By enabling users to screen themselves for dementia and access quality care, Mindstep aims to overcome traditional healthcare capacity limitations, effectively placing a digital clinic in every patient's pocket.
Akura Medical
Series A in 2022
Akura Medical develops next-generation thrombectomy devices designed to simplify clot removal with a single-pass procedure, offering an easy-to-use solution to efficiently remove blood clots. The company also provides a range of surgical, medical, dental, and veterinary instruments to support clinicians in addressing venous thromboembolism and other clot-related conditions across diverse patient populations.
Elemy
Series B in 2021
Elemy is a nationwide provider of childhood behavioral and mental healthcare, specializing in autism care since its launch in April 2020. The company has expanded its services to address a range of developmental and mental health issues, including ADHD, OCD, depression, and social anxiety. Elemy employs a technology-driven care model that modernizes traditional systems by offering in-home and online Applied Behavior Analysis (ABA) services. This approach enhances accessibility and clinical outcomes while reducing costs. The platform features free autism assessments and matches children with therapists to create individualized treatment plans tailored to their specific needs. Elemy's multidisciplinary clinical team oversees an integrated care model, demonstrating significant improvements in behavior for many children.
Tioga Cardiovascular
Series B in 2021
Tioga Cardiovascular is a privately held company that specializes in developing valve replacement solutions for mitral and tricuspid applications. The company focuses on creating medical equipment technology that employs a transcatheter approach, which is both procedurally simpler and less invasive than traditional methods. By prioritizing innovation in valve replacement devices, Tioga Cardiovascular aims to enhance the effectiveness and success of heart surgeries, thereby improving patient outcomes and providing elegant solutions for healthcare professionals.
Myra Vision
Series A in 2021
Myra Vision develops innovative surgical techniques aimed at enhancing glaucoma treatment. Its core technology enables significant intraocular pressure reduction while minimizing the risk of hypotony, offering physicians an improved platform for treating moderate to advanced glaucoma.
Myra Vision
Series A in 2021
Myra Vision develops innovative surgical techniques aimed at enhancing glaucoma treatment. Its core technology enables significant intraocular pressure reduction while minimizing the risk of hypotony, offering physicians an improved platform for treating moderate to advanced glaucoma.
Collective Health
Series F in 2021
Collective Health is a health benefits platform that integrates various medical, dental, vision, and pharmacy services into a cohesive solution aimed at simplifying healthcare for employees and their families. The company’s cloud-based platform streamlines the administration of health plans through a single portal, offering clear guidance, live concierge support, and digital tools for managing care. By reducing the administrative burden associated with health benefits, Collective Health enhances the member experience and aids organizations in controlling costs while improving health outcomes. Headquartered in San Francisco, California, the company also has offices in Chicago, Illinois, and Lehi, Utah.
Supira Medical
Series B in 2020
Supira Medical develops a percutaneous ventricular assist device (pVAD) designed to provide temporary mechanical support during high-risk coronary interventions and cardiogenic shock. Its solution assists the native pumping action of the heart, enabling patients to undergo necessary procedures.
CloudCath
Series A in 2020
CloudCath is a company that specializes in developing a sensor-enabled digital platform tailored for patients undergoing peritoneal dialysis. The platform integrates Internet of Things-based sensing hardware with a continuous monitoring system, allowing for the early detection of complications associated with catheter-based treatments. This innovative approach not only enhances patient care by enabling healthcare providers to monitor patients remotely during their home treatments but also aims to reduce the frequency of in-person visits required each month. By focusing on early complication detection, CloudCath seeks to improve patient outcomes in the management of dialysis therapy.
Palantir Technologies
Venture Round in 2019
Palantir Technologies develops data fusion, integration, and analytics software for public institutions, commercial enterprises, and non-profit organizations worldwide. The company offers Gotham, a platform that integrates, manages, secures, and analyzes enterprise data, and Metropolis, a platform that integrates, enriches, models, and analyzes quantitative data for commercial use. Palantir's software supports activities such as anti-fraud, crisis response, cyber security, defense, disaster preparedness, disease response, healthcare delivery, intelligence, law enforcement, insurance analytics, and pharmaceutical research. Its solutions enable collaboration across and within organizations to make sense of large and complex data sets. Palantir serves government, defense, finance, healthcare, and other industries. The company was founded in 2003 and is based in Palo Alto, California.
Atia Vision
Series D in 2019
Atia Vision, Inc. is a medical device company based in Campbell, California, specializing in the development of innovative ophthalmic solutions. Founded in 2012, the company focuses on creating modular presbyopia-correcting intraocular lenses, which address the needs of the intraocular lens replacement market. Atia Vision's technology features an accommodating base that responds to the ciliary muscles of the eye, simulating natural accommodation and allowing for subsequent refractive corrections. This approach restores the full range of functional vision for cataract patients, effectively improving patient outcomes by eliminating the need for glasses. The company's commitment to advancing eye care is reflected in its goal to enhance the quality of life for individuals through innovative medical devices that expedite market entry while minimizing risk.
Tioga Cardiovascular
Series A in 2019
Tioga Cardiovascular is a privately held company that specializes in developing valve replacement solutions for mitral and tricuspid applications. The company focuses on creating medical equipment technology that employs a transcatheter approach, which is both procedurally simpler and less invasive than traditional methods. By prioritizing innovation in valve replacement devices, Tioga Cardiovascular aims to enhance the effectiveness and success of heart surgeries, thereby improving patient outcomes and providing elegant solutions for healthcare professionals.
NuVera Medical
Seed Round in 2019
NuVera Medical, Inc. is a privately held company based in Campbell, California, founded in 2016. It specializes in developing an advanced imaging platform that utilizes 4D ultrasound technology for cardiovascular procedures. The platform is designed for real-time intracardiac echocardiography, enabling healthcare specialists to visualize heart chambers during transcatheter cardiac interventions. By simplifying complex cardiovascular procedures, NuVera Medical aims to support cardiologists in making informed decisions throughout their interventions.
Uber Advanced Technologies Group
Venture Round in 2019
Founded in 2019, Uber Advanced Technologies Group is a subsidiary of Uber Technologies, Inc. It focuses on commercializing self-driving ridesharing services, aiming to bring safe and reliable autonomous transportation to users worldwide.
Atia Vision
Series C in 2018
Atia Vision, Inc. is a medical device company based in Campbell, California, specializing in the development of innovative ophthalmic solutions. Founded in 2012, the company focuses on creating modular presbyopia-correcting intraocular lenses, which address the needs of the intraocular lens replacement market. Atia Vision's technology features an accommodating base that responds to the ciliary muscles of the eye, simulating natural accommodation and allowing for subsequent refractive corrections. This approach restores the full range of functional vision for cataract patients, effectively improving patient outcomes by eliminating the need for glasses. The company's commitment to advancing eye care is reflected in its goal to enhance the quality of life for individuals through innovative medical devices that expedite market entry while minimizing risk.
Supira Medical
Series A in 2018
Supira Medical develops a percutaneous ventricular assist device (pVAD) designed to provide temporary mechanical support during high-risk coronary interventions and cardiogenic shock. Its solution assists the native pumping action of the heart, enabling patients to undergo necessary procedures.
NuVera Medical
Series A in 2017
NuVera Medical, Inc. is a privately held company based in Campbell, California, founded in 2016. It specializes in developing an advanced imaging platform that utilizes 4D ultrasound technology for cardiovascular procedures. The platform is designed for real-time intracardiac echocardiography, enabling healthcare specialists to visualize heart chambers during transcatheter cardiac interventions. By simplifying complex cardiovascular procedures, NuVera Medical aims to support cardiologists in making informed decisions throughout their interventions.
Cerestra
Acquisition in 2016
Cerestra is a private equity firm that specializes in investing in real estate assets that are socially relevant and critical for business. The firm focuses on sectors such as K-12 education infrastructure, student housing, life sciences real estate, and industrial light manufacturing facilities. By providing a platform for innovative and risk-mitigated investment opportunities, Cerestra aims to create a unique investment landscape that fosters strong relationships and proprietary strategies. Through its targeted approach, the firm seeks to address essential needs within these sectors while delivering value to its investors.
Northgate Capital
Acquisition in 2016
Northgate Capital, established in 2000, is a global investment firm with offices in San Francisco, London, and Mexico City. It manages approximately $4.8 billion in assets and employs over 50 investment professionals. The firm specializes in venture capital, offering both fund-of-funds and direct investment strategies, and also operates in private equity, focusing on global small market fund-of-funds, Mexico growth equity, and mezzanine finance.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.